Austin, TX, March 27, 2025 – Courage Unmasked podcast welcomes Dr. Lingbing Zhang and Dr. Suzanne Kennedy, co-founders of Akexis, for a compelling conversation on their groundbreaking work to combat cancer cachexia—a devastating muscle-wasting condition that robs late-stage cancer patients of their strength and dignity.

In the episode "From Loss to Breakthrough: How Two Researchers Are Redefining Cancer Survival,"  Dr. Zhang and Dr. Kennedy share their deeply personal motivation behind their research.

Dr. Zhang shares, "Just in the U.S., more than 1,600 people die of cancer every day. One day is normal for us, but for people suffering from late-stage cancer with cachexia, this is their last day. I think this is the purpose of my life. We are going to make a difference for patients."

Together, Dr. Zhang and Dr. Kennedy discuss how Akexis is pioneering new therapies to transform cancer care and improve patient outcomes. Their journey—from personal loss to scientific breakthroughs—is a testament to the power of innovation and determination in the fight against cancer.

Listen to the full episode here: https://www.commix.io/blog/akexis-cancer-cachexia-research

About Akexis:
Akexis is a biotechnology company dedicated to developing transformative cancer therapeutics. Led by a team of seasoned scientists, clinicians, and innovators, Akexis is committed to advancing solutions that address the highly unmet needs of late-stage cancer patients. Akexis’s mission is to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable and curable condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@akexis.com.